FibroTest-ActiTest

Your liver can lose a third of its working tissue to scar buildup before routine blood work looks abnormal. Standard liver enzyme tests tell you that damage is happening right now, but they say almost nothing about how much permanent scarring has accumulated over months or years. That distinction matters, because scarring (fibrosis) is what drives liver disease toward cirrhosis, a state where so much scar tissue has replaced working liver that the organ begins to fail.

The FibroTest-ActiTest panel answers both questions in a single blood draw. It feeds six blood markers into two validated algorithms: one that estimates fibrosis stage (how much scar tissue has built up) and one that estimates inflammatory activity (how aggressively the liver is being damaged right now). Together, they give you a picture that previously required a needle biopsy to obtain.

What This Panel Reveals

The panel covers two distinct clinical domains that map directly onto the two things a hepatologist (a liver specialist) needs to know about any chronic liver condition: structure and activity.

The FibroTest Score estimates fibrosis on a scale from 0 to 1, corresponding to the METAVIR scale, a grading system pathologists use to classify liver biopsy samples (F0 through F4, where F0 means no fibrosis and F4 means cirrhosis). It draws on five of the panel's blood markers, each chosen because fibrosis predictably shifts its concentration. As scar tissue accumulates, the liver produces more of certain large proteins, clears others less efficiently, and alters its output of transport molecules. The algorithm captures these shifts and translates them into a single number.

The ActiTest Score estimates inflammatory activity on a scale from 0 to 1, corresponding to METAVIR grades A0 through A3. It uses the same five markers as FibroTest plus ALT (alanine aminotransferase), the classic enzyme released when liver cells are actively being destroyed. Adding ALT lets the algorithm distinguish between a liver that is scarred but quiet and one that is scarred and still under attack.

Why These Markers Together

No single blood test can reliably stage liver fibrosis. ALT can be normal even with advanced scarring. GGT (gamma-glutamyl transferase) rises with many liver insults but does not distinguish mild injury from severe fibrosis. The power of FibroTest comes from combining markers that move in different directions as fibrosis progresses, creating a pattern that a single test cannot replicate.

Alpha-2-macroglobulin, a large protein made by the liver, rises as fibrosis worsens because specialized liver cells called hepatic stellate cells, which drive scar formation, increase its production. Haptoglobin, a protein that binds and removes damaged hemoglobin (the oxygen-carrying molecule in red blood cells), falls as fibrosis progresses because the scarred liver clears it less effectively. Apolipoprotein A1 (ApoA1), the main protein component of HDL ('good') cholesterol, also declines with advancing fibrosis as the liver's ability to produce proteins drops.

GGT and total bilirubin add information about bile flow and detoxification. When scarring disrupts the liver's internal plumbing, GGT rises and bilirubin clearance slows. The algorithm weighs all five signals, adjusted for age and sex, to generate a fibrosis estimate that has been validated against liver biopsy in large studies.

How to Read Your Results Together

The two scores are the headline numbers, but the individual components help you understand what is driving them and whether a result might be misleading. Here are the patterns that matter most.

When interpreting FibroTest, scores between 0.32 and 0.48 fall in a gray zone where the test cannot confidently distinguish F1 from F2. In a meta-analysis of FibroTest across multiple chronic liver diseases, the area under the receiver operating characteristic curve (a measure of diagnostic accuracy where 1.0 is perfect and 0.5 is no better than a coin flip) for detecting significant fibrosis (F2 or higher) was 0.84. That level of accuracy is comparable to a second liver biopsy read by a different pathologist, since biopsy itself has a well-documented sampling error rate.

When Results Can Be Misleading

Several conditions can shift one or more of the panel's components in ways that distort the composite scores. The most common is Gilbert syndrome, a harmless genetic condition in which bilirubin runs high. Because elevated bilirubin pushes the FibroTest algorithm toward a higher fibrosis estimate, people with Gilbert syndrome may receive a falsely elevated score. About 5% to 10% of the general population carries this variant.

Hemolysis (the premature breakdown of red blood cells) drops haptoglobin independently of liver disease, which can also inflate FibroTest. Acute systemic inflammation from any cause, such as a severe infection, can raise alpha-2-macroglobulin and lower haptoglobin at the same time, mimicking a fibrotic pattern. For this reason, the test should be drawn when you are not acutely ill.

Certain medications can also interfere. Drugs that cause cholestasis (impaired bile flow) raise GGT and bilirubin. Statins and other medications that can damage the liver may elevate ALT, which would inflate the ActiTest score without reflecting true chronic liver inflammation. If you take any of these, mention them when discussing results with your clinician.

Who Has Been Studied

FibroTest was originally developed and validated in people with chronic hepatitis C. The landmark 2001 study in The Lancet enrolled 339 patients with hepatitis C and demonstrated that a combination of five serum markers could identify significant fibrosis with an area under the curve of 0.84. Since then, validation has expanded to chronic hepatitis B, alcoholic liver disease, and non-alcoholic fatty liver disease (NAFLD).

A 2005 head-to-head comparison in Gastroenterology found that FibroTest performed comparably to transient elastography (a specialized ultrasound-based technique that measures liver stiffness) for staging fibrosis in 183 patients with hepatitis C. The two methods agreed on fibrosis stage in the majority of cases, and combining them reduced the need for biopsy.

European Association for the Study of the Liver (EASL) guidelines include FibroTest among the recommended non-invasive tools for evaluating liver disease severity. French national guidelines have endorsed it as a first-line alternative to biopsy for hepatitis C since 2002.

Tracking Over Time

A single FibroTest-ActiTest result is a snapshot. Serial testing turns it into a trajectory. If you are treating fatty liver disease with weight loss, managing hepatitis B with antivirals, or reducing alcohol intake, repeating the panel every 6 to 12 months lets you see whether fibrosis is stable, improving, or progressing despite intervention.

Studies tracking FibroTest over 5 to 10 years in patients with hepatitis C have shown that changes in the score predict clinical outcomes. A declining FibroTest after antiviral treatment correlates with improvement confirmed on follow-up biopsy. A rising score, even if it stays below the cirrhosis threshold, signals that the current management approach is not working and needs to change.

For people using this panel to monitor NAFLD (the most common chronic liver condition worldwide, affecting roughly 25% of adults), serial tracking is especially valuable because NAFLD progression is slow and symptoms appear late. A stable or declining FibroTest score over two to three years provides reassurance that lifestyle changes are protecting the liver's structure.

What to Do with Your Results

If both scores fall in the low range (FibroTest below 0.31, ActiTest below 0.36), your liver shows no evidence of significant scarring or active inflammation. Continue monitoring annually if you have any ongoing risk factor: obesity, type 2 diabetes, regular alcohol use, or chronic viral hepatitis.

If either score lands in the indeterminate zone (FibroTest 0.32 to 0.48), consider adding transient elastography (FibroScan) to clarify the fibrosis stage. The combination of a blood-based score and an imaging-based measurement reduces diagnostic uncertainty to the point where fewer than 20% of cases still need biopsy.

If FibroTest is above 0.48, a consultation with a liver specialist is the right next step. Scores in this range correspond to at least moderate fibrosis, and the higher the score, the more urgent the evaluation. A hepatologist may recommend imaging, additional blood work, or in some cases a biopsy to confirm staging and guide treatment decisions.

If ActiTest is elevated but FibroTest is low, the priority shifts to identifying and removing the source of ongoing liver injury. This is the best possible scenario for intervention: the liver is inflamed but not yet significantly scarred, which means removing the cause (alcohol, a liver-damaging medication, or poorly controlled blood sugar and cholesterol) can halt progression before permanent damage accumulates.